Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma


  • Alan P. Venook M.D.

    Corresponding author
    1. Department of Medicine, University of California–San Francisco, San Francisco, California
    • Department of Medicine, University of California, San Francisco, 1600 Divisadero, Box 1705, San Francisco, CA 94115
    Search for more papers by this author
    • Fax: (415) 353-9959

    • Alan P. Venook is a consultant with Genentech and is a member of the Speakers Bureaus of Sanofi, Roche, Pfizer, and Genentech.


Substantial effort has focused on the development of novel targeted agents for treating patients with late-stage colorectal carcinoma. These agents are designed specifically to inhibit biochemical processes associated with pathogenesis. Numerous molecules targeting the epidermal growth factor receptor have been investigated as therapeutic agents and appear to herald a shift in the treatment paradigm for colorectal carcinoma. Cancer 2005. © 2005 American Cancer Society.